

PROVIDERUpdate



CONTRACTUAL | MARCH 26, 2025 | UPDATE 25-268m | 3 PAGES

Updates to Medicare Clinical and Medical Policies – April 2025

Stay compliant by reviewing changes to medical policies for Medicare

The medical policies listed in this update were approved by Centene's National Medicare Quality Improvement Utilization Management Committee and are effective as of April 2025.

For a complete description of the background, criteria, references, and coding implications for these Medicare medical policies, go to the Medicare Prior Authorization Medical Clinical Policies page at bit.ly/MA_ClinicalPolicies.

Apply the Medicare National Coverage Decisions (NCDs) and applicable Local Coverage Decisions (LCDs) local policies for primary coverage guidance.

Inactive policy

The following policy is no longer active as of April 2025.

Policy number	Policy name
MC.CP.MP.182	Short Inpatient Hospital Stay

Refer to pages 2-3 for a list of medical policies and genetic Medicare policies, effective April 2025.

Additional information

If you have questions regarding the information contained in this update, contact the Provider Services Center by email at provider_services@healthnet.com, by telephone or through the provider portal as listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Behavioral Health Providers

LINES OF BUSINESS:

- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)

PROVIDER SERVICES

provider_services@healthnet.com

**Medicare (individual & employer group)
(Wellcare By Health Net) – 800-929-9224**

Medicare Supplement – 800-641-7761

**Behavioral Health providers –
844-966-0298**

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

Medical policies, effective April 2025

The following are Medicare clinical policies that have been approved for use. The listed policies are effective April 2025.

Updated Policies

Policy number and name	Change
MC.CP.MP.190 Outpatient Oxygen Use	• Annual review. • Removed criteria I.C. The qualifying blood gas study or pulse oximetry measurement was performed by a physician or by a qualified provider or supplier of laboratory services. • Minor edits to background with no impact to criteria. • Added CPT E0447 to coding table. • References reviewed and updated. • Reviewed by external specialist.
MC.CP.MP.22 Stereotactic Radiation SRS and SBRT	• Added risk/benefit statement. • Added criteria III.E.1-III.E.4. • Extracranial oligometastatic disease, any of the following: One to three metastatic lesions involving the lungs, liver or bone; primary tumor is breast, colorectal, melanoma, non-small cell lung, prostate, renal cell or sarcoma; primary tumor is controlled; no prior history of metastatic disease. III.F. Acoustic neuroma; III.G. spinal tumors.
MC.CP.MP.247 Transplant Service Documentation Requirements	• Background updated with no impact on criteria. • References reviewed and updated. • Reviewed by external specialist
MC.CP.MP.248 Facility Based Sleep Studies	• Updated wording in Criteria I.B.8.a.v. and added addition of disorders that interfere with HSAT. • Removed “moderate to high-risk” verbiage in Criteria I.B.8.b. and updated outline of criteria. • Removed Epworth Sleepiness Scale criteria from I.B.8.b.i. • Added Criteria I.B.8.b.ii.c) which states, “Diagnosis of hypertension.”

Concert Genetic Medicare Policies

The following are genetic testing policies that have been approved for use (refer to the revision log within the policy for list of policy updates).

Algorithmic Testing	Hearing Loss
Aortopathies and Connective Tissue Disorders	Hematologic Conditions (non-cancerous)

Concert Genetic Medicare Policies, *continued*

Cancer Screening	Hereditary Cancer Susceptibility
Cardiac Disorders	Immune, Autoimmune, and Rheumatoid Disorders
Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy)	Kidney Disorders
Cytogenetic Testing	Lung Disorders
Dermatologic Conditions	Metabolic, Endocrine, and Mitochondrial Disorders
Epilepsy, Neurodegenerative, and Neuromuscular Conditions	Molecular Analysis of Solid Tumors and Hematologic Malignancies
Exome and Genome Sequencing for the Diagnosis of Genetic Disorders	Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay
Eye Disorders	Non-invasive Prenatal Screening (NIPS)
Gastroenterologic Disorders (non-cancerous)	Pharmacogenetics
General Approach to Genetic and Molecular Testing	